The Trump administration has proposed restricting generic drug exclusivity as a way to increase competition and lower prices, but attorneys told me this proposal could actually backfire and lead to less generic competition.
The first company to file a generic application at the FDA gets 180 days of exclusivity for their product, meaning that in general no other generic can be sold for a lucrative half-year period once the branded drug loses patent protection. But sometimes a generic maker will essentially park its exclusivity and not sell the drug, meaning the second and subsequent companies cannot reach the market and help lower a drug’s cost.
Generic drugmakers park exclusivity because they sometimes enter agreements with branded drugmakers, called pay-for-delay agreements. Under these agreements, a branded drugmaker pays the generic company to keep its generic off the market for a period of time and if the generic company has exclusivity, other companies also can’t bring their generic versions to market.
In the 2019 budget request released Feb. 12, the administration proposed to essentially start the exclusivity period’s clock running even if a first-filing generic company hasn’t started selling its drug yet. The proposal would make the tentative approval of a second generic drug, if it’s blocked by the first filer’s behavior, a trigger of the first applicant’s 180-day exclusivity.
But Kurt Karst, an attorney at Hyman, Phelps & McNamara in Washington who advises drugmakers, told me profit margins for the generic industry are very low and the proposal would cut into one incentive that companies rely on.
“Ultimately you may end up with less generic competition” because of the proposal, attorney Chad A. Landmon told me. Landmon, an intellectual property and food and drug law attorney, is with Axinn, Veltrop & Harkrider LLP in Hartford, Conn., and Washington.
Read my full article here.
Stay on top of new developments in health law and regulation, and learn more, by signing up for a free trial to Bloomberg Law.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)